BR0314223A - Compostos fenil-indol para modular ige e inibir proliferação celular - Google Patents

Compostos fenil-indol para modular ige e inibir proliferação celular

Info

Publication number
BR0314223A
BR0314223A BR0314223-0A BR0314223A BR0314223A BR 0314223 A BR0314223 A BR 0314223A BR 0314223 A BR0314223 A BR 0314223A BR 0314223 A BR0314223 A BR 0314223A
Authority
BR
Brazil
Prior art keywords
cell proliferation
ige
inhibit cell
phenyl
indole compounds
Prior art date
Application number
BR0314223-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jagadish C Sircar
Jailall Ramnauth
Mark L Richards
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BR0314223A publication Critical patent/BR0314223A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314223-0A 2002-09-12 2003-09-12 Compostos fenil-indol para modular ige e inibir proliferação celular BR0314223A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41077702P 2002-09-12 2002-09-12
PCT/US2003/030959 WO2004024896A2 (en) 2002-09-12 2003-09-12 Phenyl-indole compounds

Publications (1)

Publication Number Publication Date
BR0314223A true BR0314223A (pt) 2005-07-26

Family

ID=31994205

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314223-0A BR0314223A (pt) 2002-09-12 2003-09-12 Compostos fenil-indol para modular ige e inibir proliferação celular

Country Status (16)

Country Link
US (1) US7375118B2 (enExample)
EP (1) EP1537079A4 (enExample)
JP (1) JP2006512293A (enExample)
KR (1) KR20050051658A (enExample)
CN (1) CN1694868A (enExample)
AR (1) AR041251A1 (enExample)
AU (2) AU2003270426A1 (enExample)
BR (1) BR0314223A (enExample)
CA (1) CA2498493A1 (enExample)
MX (1) MXJL05000009A (enExample)
PE (1) PE20050035A1 (enExample)
PL (1) PL375812A1 (enExample)
RU (1) RU2005109912A (enExample)
TW (1) TW200407303A (enExample)
WO (2) WO2004024655A2 (enExample)
ZA (1) ZA200502739B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
DE60221804T2 (de) * 2001-03-12 2008-05-15 Avanir Pharmaceuticals, San Diego Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎を治療するための方法
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
ITMI20061368A1 (it) * 2006-07-14 2008-01-15 Acraf Composto 2-arilindolico sostituito in posizione 5, composizione farmaceutica che lo comprende nonche' composti intermedi e procedimento per prepararlo
RU2015115677A (ru) * 2012-10-17 2016-12-10 Ф. Хоффманн-Ля Рош Аг Производные 6-аминоиндола в качестве антагонистов канала с транзиторным рецепторным потенциалом (trp)
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) * 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
PL3723790T3 (pl) * 2017-12-12 2024-05-13 Kamada Ltd Sposoby indukowania tolerancji immunologicznej i redukcji odpowiedzi przeciwciała antylekowego
WO2020078454A1 (en) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Method of modulating autoimmunity by disrupting cis‐ligand binding of siglec type antigens
CA3176436A1 (en) 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
JP2023542289A (ja) 2020-09-10 2023-10-06 ジェンマブ エー/エス 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
CN116406293A (zh) 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー/エス 慢性リンパ球性白血病を治療するためのcd3及びcd20に対する二重特異性抗体
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2023542291A (ja) 2020-09-10 2023-10-06 ジェンマブ エー/エス びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
TWI909603B (zh) * 2023-08-09 2025-12-21 南韓商大熊製藥股份有限公司 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4510158A (en) * 1984-03-05 1985-04-09 Sterling Drug Inc. 2-Phenylindole derivatives, their use as complement inhibitors
DE3680636D1 (de) 1985-05-03 1991-09-05 Foxboro Co Regelung des trennungspunktes bei der destillation.
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US5206257A (en) 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
JPH03500050A (ja) 1988-02-02 1991-01-10 シェリング・バイオテック・コーポレーション 免疫グロブリンeの応答を減少させる方法
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
FR2658511B1 (fr) 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
AU8225991A (en) 1990-07-31 1992-03-02 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
EP0469477B1 (en) 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5656762A (en) 1990-12-28 1997-08-12 Neurogen Corporation 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands
JPH06263993A (ja) 1991-01-21 1994-09-20 Konica Corp アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5322847A (en) 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
CZ104795A3 (en) 1994-04-29 1996-02-14 Lilly Co Eli Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DE19503160A1 (de) 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
KR100447539B1 (ko) 1995-08-02 2004-11-10 뉴캐슬 유니버시티 벤처스 리미티드 벤조이미다졸화합물과이를포함하는제약학적조성물및이화합물을이용한치료방법
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
AU4988997A (en) 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2232467A1 (en) 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
ID24054A (id) 1997-06-10 2000-07-06 Glaxo Group Ltd Glaxo Turunan turunan benzimidazol
GB9718833D0 (en) * 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
US6093728A (en) 1997-09-26 2000-07-25 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6303645B1 (en) 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
JP2002516276A (ja) 1998-05-22 2002-06-04 アバニール・ファーマシューティカルズ IgEのモジュレータとしてのベンゾイミダゾール誘導体
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
HK1041483B (zh) 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 雙環氮雜環
ES2234318T3 (es) 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
US6509365B1 (en) * 1998-11-17 2003-01-21 Basf Aktiengesellschaft 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
NZ511825A (en) 1998-11-27 2003-08-29 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
SK287807B6 (sk) 2001-03-12 2011-10-04 Janssen Pharmaceutica N. V. Spôsob prípravy 4-(3-chlórfenyl)-6-[(4-chlórfenyl)hydroxy(1- metyl-1H-imidazol-5-yl)metyl]-1-metyl-2(1H)-chinolinónu
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
DE60221804T2 (de) 2001-03-12 2008-05-15 Avanir Pharmaceuticals, San Diego Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
PL378919A1 (pl) 2003-04-10 2006-06-12 Avanir Pharmaceuticals Pochodne imidazolu do leczenia zaburzeń alergicznych i nadmiernego rozrostu
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Also Published As

Publication number Publication date
PL375812A1 (en) 2005-12-12
AR041251A1 (es) 2005-05-11
CN1694868A (zh) 2005-11-09
WO2004024655A2 (en) 2004-03-25
PE20050035A1 (es) 2005-01-24
RU2005109912A (ru) 2006-04-27
MXJL05000009A (es) 2005-06-07
TW200407303A (en) 2004-05-16
CA2498493A1 (en) 2004-03-25
ZA200502739B (en) 2005-10-13
EP1537079A2 (en) 2005-06-08
US20040180946A1 (en) 2004-09-16
EP1537079A4 (en) 2007-05-16
JP2006512293A (ja) 2006-04-13
AU2003270426A1 (en) 2004-04-30
AU2003277152A1 (en) 2004-04-30
US7375118B2 (en) 2008-05-20
KR20050051658A (ko) 2005-06-01
WO2004024896A2 (en) 2004-03-25
WO2004024896A3 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
BR0314223A (pt) Compostos fenil-indol para modular ige e inibir proliferação celular
BR0314235A (pt) Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular
BR0208010A (pt) Composto de benzimidazol para modulação de ige e inibição de proliferação celular
BR9910641A (pt) Derivados de benzimidazol como moduladores de ige
BR112022022524A2 (pt) Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
MA31167B1 (fr) Inhibiteurs de l'activite de akt
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
CR20240189A (es) Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y usos de los mismos
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
BR0313396A (pt) 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
JOP20240096A1 (ar) مثبطات صغيرة الجزيئات لبروتياز نوعي ليوبيكويتين 1 (usp1) واستخداماتها
ATE448189T1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
ATE410408T1 (de) Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
BRPI0517033A (pt) novos derivados de hidantoìna como inibidores de metaloproteinase
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69942575D1 (de) Nukleinsäuremolekül, die für die alpha-kettedes pferde-fc-epsilon-rezeptors kodieren, korrespondierende proteine und ihre verwendungen
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.